NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will ...

- Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance of pro forma 2025 combined revenues, now estimated to be in the range of $325 to $350 million - - Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million - BERKELEY HEI ...

PRINCETON, N.J., Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President and Chief Executive Officer, has been invited to deliver a corporate presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September ...

JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025.Six-Month 2025 Financial Summary  Revenues for the six months ended Jun ...

Core Insights - Veeva Systems has seen significant adoption of its Veeva RIM platform, with over 450 companies, including 19 of the top 20 biopharmaceutical firms, utilizing it for regulatory information management [1][6] - The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to enhance connectivity and integration with multiple health authority platforms, aiming to improve efficiency and compliance in regulatory processes [1][4][5] Veeva RIM Adoption and Impact - The adoption of Veeva RIM is helping regulatory teams improve efficiency and reduce cycle times, providing an end-to-end solution that accelerates time to market and enhances collaboration among global stakeholders [2][3] - More than 85 organizations are leveraging Veeva Submissions Publishing to implement continuous publishing, which reduces rework and accelerates submission timelines [3] Strategic Partnerships - The partnership with Accumulus Technologies aims to modernize information sharing with over 70 regulatory agencies worldwide, facilitating seamless regulatory submissions and expediting treatment delivery to patients [4] - Integrating DNAnexus Trusted Regulatory Spaces with Veeva RIM is expected to enhance data sharing capabilities for inter-agency collaboration and expedite regulated product approvals [5] Company Overview - Veeva Systems provides cloud-based software, data, and consulting services tailored for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotechs [6]

WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September. 2025 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Thursday, September ...

LA JOLLA, Calif., Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET.A li ...

Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer a ...

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Mr. London is scheduled to present at the 2 ...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately. “We’re thrilled to welcome Misbah as Maze’s Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including da ...